Renal Cell Carcinoma

• Autore: López José I
• Pubblicazione: MDPI - Multidisciplinary Digital Publishing Institute, 2020
• Descrizione fisica: 1 online resource (500 p.)
• Soggetto topico: Biology, life sciences
• Soggetto non controllato: 11) translocation renal cell carcinoma; ALK; AMP-activated protein kinases; anaplastic lymphoma kinase rearrangement; aurora A; biomarker; cancer immunotherapy; cancer-specific survival; CDKN1A expression; checkpoint inhibitors; chromophobe renal cell carcinoma; chromosomal loss; chronic kidney disease; circular RNAs in a clinico-genomic predictive model; clear cell renal cell carcinoma; clear cell Renal Cell Carcinoma; collecting duct carcinoma; copy number alteration; copy number analysis; copy number loss; curcumin; cytoreductive nephrectomy; diagnostic and prognostic markers; drug sensitivity; efficacy; emerging entity; EMT like; eosinophilic variant; ESC; everolimus; EVI1; experimental validation of circular RNA; FISH; FOXO3; gene expression; gene signature; genetic association; ghrelin; glutathione metabolism; glutathione transferase omega 1; glutathione transferase omega 2; glycomarkers; glycoproteomics; HOT; hyperosmolality; identification of circular RNAs; IL-1?; IL-2; IL13R?1; IL4R?; immune checkpoint inhibitors; immune infiltration; immunohistochemistry; immunotherapy; inflammation markers; integrins; intratumour heterogeneity; invasion; JAK2; kidney; kidney cancer; label-free; LOT; metabolic reprogramming; metabolome; metabolome profiling; metastasis; metastatic ccRCC; microRNA; miR-133b; miR-146a-5p; miR-155-5p; MiT family translocation renal cell carcinoma; MMP-9; MMP10; molecular genetic features; MTA2; mTOR; mTOR inhibitors; mutation; N-glycomapping; n/a; nephrectomy; new entity; NK cells; oncocytic renal tumor; overall survival; pale cell; Papillary renal cell carcinoma (pRCC); patient survival; PBRM1; PD-L1; pentose phosphate pathway; PI3K/Akt/mTOR; polybromo-1; polymorphism; PPP; practical approach; predictive factors; predictive role; pro-IL-1?; prognosis; prognostic factors; programmed death-ligand 1; proliferation; proteome profiling; Raf/MEK/ERK; RCC; recurrence free survival; recurrence-free survival; renal cancer; renal cell; renal cell cancer; renal cell carcinoma; review; RNA sequencing; sarcomatoid; SMAD proteins; solute carrier proteins; statins; survival; survival prediction; t(6; targeted therapy; TCA cycle; TCGA; TFE3; TFEB; TFEB-amplified renal cell carcinoma; toxicity; transforming growth factor beta; tumor adhesion; tumor microenvironment; tumor migration; tumor slice culture; tyrosine kinase inhibitors; unclassified renal cell carcinoma; unclassified renal tumor; uric acid; urine; VEGF inhibitors; von Hippel-Lindau; Xp11 translocation renal cell carcinoma
• Sommario/riassunto: Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70-80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe-oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.
• Titolo autorizzato: Renal Cell Carcinoma
• ISBN: 3-03928-639-0
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910404087003321
• Lo trovi qui: Univ. Federico II